Literature DB >> 15090562

Association between apolipoprotein E e4 allele and arteriosclerosis, cerebral amyloid angiopathy, and cerebral white matter damage in Alzheimer's disease.

J Tian1, J Shi, K Bailey, C L Lendon, S M Pickering-Brown, D M A Mann.   

Abstract

OBJECTIVE: To investigate the association between white matter damage, as evidenced by myelin loss (ML), the extent of cerebral amyloid angiopathy (CAA), or arteriosclerosis (Art), and apolipoprotein E (ApoE) e4 allele in Alzheimer's disease (AD), in order to understand the causes of damage to white matter in AD and its contribution to the pathogenesis of the disorder.
MATERIALS AND METHODS: Brain tissues were obtained from 94 patients with AD confirmed by autopsy. ApoE genotyping was performed by PCR on DNA extracted from frontal cortex or cerebellum. CAA and Art were assessed on Weigert's haematoxylin and eosin stained sections in frontal, temporal, parietal, and occipital cortices; the extent of ML was scored on Luxol fast blue stained sections of these regions.
RESULTS: The ApoE e4 allele frequency in the 61 patients with ML was not significantly different from that in the 33 patients without ML, nor did this differ in the 84 patients with Art from that in the 10 patients without Art. There were no significant differences in the proportions of patients with genotypes containing 0, 1, or 2 ApoE e4 alleles in the presence or absence of ML or Art. The mean ML, Art, or CAA scores within each region, and the total scores summed across all four brain regions, did not differ between patients with 0, 1, or 2 ApoE e4 alleles. However, the mean ML severity score in the occipital cortex was significantly greater than that in the frontal or temporal cortices in patients with 1 or 2 ApoE e4 alleles. The severity of CAA in the occipital cortex was significantly higher than that in other areas of cortex in patients with 0 or 2 ApoE e4 alleles. The mean Art score in the occipital cortex was greater than that in the temporal cortex in patients with two ApoE e4 alleles and was higher than that in the frontal cortex in patients with one ApoE e4 allele.
CONCLUSIONS: The likelihood of patients with AD suffering from CAA, Art, or ML is not influenced by ApoE e4 allele, nor is the overall burden of these pathological changes in the brain. However, the distribution of ML, CAA, and Art within the brain is at least partly influenced by genotype and dosage of ApoE e4 allele, with the occipital cortex being more severely affected by all of these pathological changes in e4 allele bearers, particularly when two ApoE e4 alleles are present.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15090562      PMCID: PMC1763560          DOI: 10.1136/jnnp.2003.012096

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  34 in total

1.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

2.  Apolipoprotein E genotyping by one-stage PCR.

Authors:  P R Wenham; W H Price; G Blandell
Journal:  Lancet       Date:  1991-05-11       Impact factor: 79.321

3.  White-matter lesions on CT in Alzheimer patients.

Authors:  D Leys; P Scheltens; M Steinling
Journal:  Acta Neurol Scand       Date:  1991-09       Impact factor: 3.209

4.  White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for heterogeneity.

Authors:  P Scheltens; F Barkhof; J Valk; P R Algra; R G van der Hoop; J Nauta; E C Wolters
Journal:  Brain       Date:  1992-06       Impact factor: 13.501

5.  Medullary arteries in aging and dementia.

Authors:  A Furuta; N Ishii; Y Nishihara; A Horie
Journal:  Stroke       Date:  1991-04       Impact factor: 7.914

6.  Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation.

Authors:  T G Ohm; M Kirca; J Bohl; H Scharnagl; W Gross; W März
Journal:  Neuroscience       Date:  1995-06       Impact factor: 3.590

7.  Alzheimer pathology of patients carrying apolipoprotein E epsilon 4 allele.

Authors:  O Heinonen; M Lehtovirta; H Soininen; S Helisalmi; A Mannermaa; H Sorvari; O Kosunen; L Paljärvi; M Ryynänen; P J Riekkinen
Journal:  Neurobiol Aging       Date:  1995 Jul-Aug       Impact factor: 4.673

8.  Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease.

Authors:  Z Nagy; M M Esiri; K A Jobst; C Johnston; S Litchfield; E Sim; A D Smith
Journal:  Neuroscience       Date:  1995-12       Impact factor: 3.590

9.  Leukoencephalopathy in diffuse hemorrhagic cerebral amyloid angiopathy.

Authors:  F Gray; F Dubas; E Roullet; R Escourolle
Journal:  Ann Neurol       Date:  1985-07       Impact factor: 10.422

10.  A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study.

Authors:  A Brun; E Englund
Journal:  Ann Neurol       Date:  1986-03       Impact factor: 10.422

View more
  7 in total

Review 1.  Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies.

Authors:  Efrat Kravitz; James Schmeidler; Michal Schnaider Beeri
Journal:  Endocrinol Metab Clin North Am       Date:  2013-09       Impact factor: 4.741

2.  ApoE E4 is a susceptibility factor in amnestic but not aphasic dementias.

Authors:  Emily Joy Rogalski; Alfred Rademaker; Theresa M Harrison; Irene Helenowski; Nancy Johnson; Eileen Bigio; Manjari Mishra; Sandra Weintraub; Marek-Marsel Mesulam
Journal:  Alzheimer Dis Assoc Disord       Date:  2011 Apr-Jun       Impact factor: 2.703

3.  Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial.

Authors:  José A Luchsinger; Thania Perez; Helena Chang; Pankaj Mehta; Jason Steffener; Gnanavalli Pradabhan; Masanori Ichise; Jennifer Manly; Davangere P Devanand; Emilia Bagiella
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

4.  Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics.

Authors:  Ramón Cacabelos; Rocío Martínez; Lucía Fernández-Novoa; Juan C Carril; Valter Lombardi; Iván Carrera; Lola Corzo; Iván Tellado; Jerzy Leszek; Adam McKay; Masatoshi Takeda
Journal:  Int J Alzheimers Dis       Date:  2012-03-14

Review 5.  The role of APOE in cerebrovascular dysfunction.

Authors:  Leon M Tai; Riya Thomas; Felecia M Marottoli; Kevin P Koster; Takahisa Kanekiyo; Alan W J Morris; Guojun Bu
Journal:  Acta Neuropathol       Date:  2016-02-16       Impact factor: 17.088

6.  Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia.

Authors:  Federica Agosta; Keith A Vossel; Bruce L Miller; Raffaella Migliaccio; Stephen J Bonasera; Massimo Filippi; Adam L Boxer; Anna Karydas; Katherine L Possin; Maria Luisa Gorno-Tempini
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-22       Impact factor: 11.205

Review 7.  Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review.

Authors:  Hannah A D Keage; Roxanna O Carare; Robert P Friedland; Paul G Ince; Seth Love; James A Nicoll; Stephen B Wharton; Roy O Weller; Carol Brayne
Journal:  BMC Neurol       Date:  2009-01-13       Impact factor: 2.474

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.